Back to Search
Start Over
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia.
- Source :
- Hematology Reports; 2017, Vol. 9 Issue 3, p87-90, 4p
- Publication Year :
- 2017
-
Abstract
- Leukemia-initiating cells of core binding factor (CBF) acute myeloid leukemia (AML) likely derive from early committed hematopoietic precursors expressing CD33. As such, targeting CD33 could ameliorate the chance of cure of CBF AML patients. We compared 12 CBF AML patients treated with Fludarabine, Cytarabine, Idarubicin and Gemtuzumab Ozogamicin (FLAI-GO regimen) with 25 CBF AML patients treated with the same schedule, but without GO. With the limit of small numbers, we observed a consistent trend toward better overall survival, disease free survival and event free survival in the FLAI-GO group. We also demonstrated the ability of GO to induce the disappearance in vitro of the AML1-ETO molecular transcript in a polymerase chain reaction-positive graft without decreasing the clonogenic potential of CD34+/CD38- cells. This represent the proof of principle for using GO in a purging strategy before autologous stem cell transplantation. Therefore, our data argue in favor of the reinstitution of GO in the therapy of CBF AML. [ABSTRACT FROM AUTHOR]
- Subjects :
- RUNX proteins
ACUTE myeloid leukemia treatment
HEMATOPOIETIC agents
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 20388322
- Volume :
- 9
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Hematology Reports
- Publication Type :
- Academic Journal
- Accession number :
- 125712501
- Full Text :
- https://doi.org/10.4081/hr.2017.7028